Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Community Stories
DMD
DM1
Careers
Investors
News
Contact
FREEDOM-DM1: Nonclinical Data Support the Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 in Adults with Myotonic Dystrophy Type 1 (DM1)
Post navigation
Previous:
Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Next:
PGN-EDODM1: Single- and Repeat-Dose Nonclinical Data Indicated Mechanistic and Meaningful Activity for Potential Treatment of Myotonic Dystrophy Type 1 (DM1)
